Ability Pharma has signed a €2.45-million investment deal with Chinese company SciClone Pharmaceuticals, which is now a shareholder in the Catalan biotechnology company. 

Collaboration between these two companies first began in 2016 with a licensing deal to develop and market the drug ABTL0812 to treat pancreatic cancer in China.

This funding, along with the €2 million the company raised through a crowdfunding campaign last December, will go to fund phase 2 clinical trials on ABTL0812.

More information

Photo: Carles Domènech, founder and president of Ability Pharma.

You may also be interested:

• Ability closes €2-million round for clinical trials on ABTL0812 to treat pancreatic cancer
• Ability receives €1.6 million from FDA and opens round on Capital Cell
• Ability Pharma raises €5 million through Horizon EIC Accelerator programme